Study of a new drug for advanced cancer
Part of Cancer clinical trials.
This study tests an experimental drug (LNF1901) for people with advanced cancers that haven't responded to standard treatments. The goal is to see if it is safe and how well it works, and it might help control the cancer or shrink tumors.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 or older.
- Your cancer is advanced and has not responded to standard treatments, or you couldn't tolerate those treatments.
- You have at least one tumor that can be measured on a scan (for the dose expansion part).
- You are physically able to care for yourself (ECOG score 0–1).
- Your overall health is good enough that you are expected to live at least 3 more months.
- Your blood counts, liver, kidney, and heart function are within acceptable ranges.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 1 trial tests NBL-020, an injected medicine, in adults with advanced solid cancers (and possibly some skin T-cell lymphoma) to see how it works and how safe it is. You may be considered if standard treatment has stopped working or isn’t tolerated and if you can provide recent tumor tissue for lab testing.
This trial tests an experimental drug (LNF2105) for people with advanced solid tumors that have stopped responding to standard treatment. The drug targets a protein called Nectin-4 on cancer cells, and participating could give you access to a new option while helping to evaluate its safety.
This trial tests a new medication for people with advanced solid tumors that have stopped responding to standard treatments. It aims to see if the drug can shrink tumors or slow their growth.
This is an early-stage study testing a new drug called JL19001, alone or combined with standard treatments, for people with advanced solid tumors (like melanoma, lung cancer, or kidney cancer) or relapsed/refractory B-cell lymphoma who have exhausted standard options. The trial aims to find the safest dose and understand how well the drug works.
This Phase 1/2 study tests an experimental medicine (RNK05047) in people with advanced solid tumors or diffuse large B‑cell lymphoma whose standard treatments haven’t worked or can’t be tolerated. It may help shrink tumors and improve control of the disease, but early-phase trials also focus on safety and dosing.
This trial tests an experimental antibody drug called SIG001 for people with advanced solid tumors that haven't responded to standard treatments. It aims to see if the drug is safe and how well it works.
Hear when a new Advanced Malignant Tumors trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.